

was not at such a high level. On the contrary, 5-fluorouracil-1-propionic acid (**4**) has practically no activity under the same testing conditions, as shown in Table 1.

Acknowledgements.

The authors wish to thank Dr. Tadayoshi Ieki (Shionogi Research Laboratories) for the fluorine analysis. These pharmacological data are the results of screening performed under the auspices of the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.

REFERENCES AND NOTES

[1] L. Bosch, H. Harbers and C. Heidelberger, *Cancer Res.*, **18**,

335 (1958).

[2] G. Bounous, R. Pageau and P. Regoli, *Int. J. Clin. Pharmacol. Biopharm.*, **16**, 519 (1978).

[3] M. Yasumoto, A. Moriyama and T. Suzue, *J. Med. Chem.*, **20**, 1592 (1977).

[4] A. Kojima, T. Yokoyama, M. Odate, Y. Ike and Kamino, Japan Kokai Tokyo Koho 78,108,987 (1978); *Chem. Abstr.*, **90**, 137855k (1979).

[5] T. Ouchi, S. Jokei and H. Chikashita, *J. Heterocyclic Chem.*, **19**, 935 (1982).

[6] R. I. Geran, N. H. Greeberg, M. M. Machdonald, A. M. Schumacher and B. J. Abbott, *Cancer Chemother. Rep.*, Part 3, 1 (1972).